The Role of the Ambulatory Care Pharmacist in the Management of COPD and Transition of Care in a Community Hospital

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • CPE: 0.75
    • Other: 0.75
  • Cost: Free
  • Release: Jun 18, 2020
  • Expires: Jun 17, 2023
  • Estimated Time to Complete:
    45 Minutes
  • Average User Rating:
    (3 Ratings)


Rachael A.  Hiday Rachael A. Hiday, PharmD, MBA, BCPS, BCACP
Clinical Pharmacist, Ambulatory Care
Indiana University Health
Affiliate Professor, Clinical Family Medicine
Indiana University School of Medicine
Indianapolis, Indiana

Sarah B.  Vickey Sarah B. Vickey, PharmD, BCACP
Outpatient Pharmacy Manager
Ephraim McDowell Health
Danville, Kentucky

Needs Statement

COPD is the 3rd leading cause of death in the US. $50 billion was spent in 2010 - 70% attributed to exacerbations. Each COPD admission/readmission costs approximately $8,400-$11,100. Barriers to quality care is a lack of education on disease state and inhaler technique and time constraints during provider visits post-hospitalization. The health care team has a key role in prevention of exacerbations/admissions.

Thirty-day readmission rates for hospitals are under surveillance because of potential reimbursement reductions. Hospital specific programs are being developed and employed by various institutions to help reduce readmission rates and improve patient outcomes.

Target Audience

Physician, Physician Assistant, Nurse, Nurse Practioner, Pharmacist, and any other health care professional treating patients with COPD. 


Upon completion of this educational activity, participants will be able to:

  • Describe the components of effective collaborative drug therapy management (CDTM) for COPD
  • Demonstrate how to perform a pharmacist-led COPD visit
  • Explain different programs available to enhance access to medications for COPD
  • Explain WHY the program at Ephraim McDowell Regional Medical Center (EMRMC) was started
  • Review the functionality of the transition of care program at EMRMC
  • Explain the benefits of the EMRMC transition of care program


The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Practice-based learning and improvement

ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-0000-20-139-H01-P and will award 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

No speakers, planners, or reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


In collaboration with UK College of Pharmacy Center for the Advancement of Pharmacy Practice.